PUBLICATION
Global Business Reports
United States Biopharmaceuticals 2018
May 31, 2018
The United States has long been recognized as the innovation capital of the world for life sciences, well supported through a favorable IP framework and garnering attention from overseas as a high-value market. Under increasing scrutiny and pressure on drug pricing, companies are adapting drug development and market entry strategies – keeping the patient at the center of the process, trends towards precision medicine, more targeted treatments and better-defined patient populations are benefitting drug development timelines and costs through higher trial success rates. As companies’ strategies shift, the U.S. healthcare system itself will have to be adapted to absorb curative therapies entering the market.
RELATED INTERVIEWS MORE INTERVIEWS
Tango Therapeutics is targeting unaddressed disease mechanisms in cancer to develop transformational new drugs for patients.
Founded in 2008, Eiger BioPharmaceuticals is a late-stage biopharmaceutical company focused on developing and commercializing targeted therapies for rare diseases.
Tosk, Inc. is a small molecule, oncology drug discovery and development company.
LabCental offers life science companies in Massachusetts at an early stage the facilities they need to develop
RELATED ARTICLES MORE ARTICLES
Finding Funding: The Diversification of the Biotech Financing Landscape
United States Biopharmaceuticals 2018
The methods of financing biotech R&D are evolving as large pharma companies and governments look to small biotech start-ups to provide the next generation of medicines.
Infectious Diseases: Addressing Growing Resistance
United States Biopharmaceuticals 2018
The infectious disease space is one of high unmet need. However, this particular market segment carries an additional challenge: drug resistance.
RECENT PUBLICATIONS
Ontario Mining and Toronto's Global Reach 2024 - Digital Interactive
GBR’s annual Ontario Mining and Toronto’s Global Reach 2024 report draws from over 100 interviews with leading executives from major producers, associations, juniors, consultants, investors, and service providers, to provide an in-depth and holistic view of what is happening now, and more pertinently, what could happen in the years ahead.
MORE PREVIOUSLY PUBLISHED
GBR’s annual Ontario Mining and Toronto’s Global Reach 2024 report draws from over 100 interviews with leading executives from major producers, associations, juniors, consultants, investors, and service providers, to provide an in-depth and holistic view of what is happening now, and more pertinently, what could happen in the years ahead.
MORE PREVIOUSLY PUBLISHED
MACIG
"We plan to double our copper production by the end of the decade. There remains significant upside potential in the gold industry, and the copper operations are strategic and additive to that."
SUBSCRIBE TO OUR NEWSLETTER
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
